ABBN.SW: $86.18 ▲ 0.08 (0.09%)ASML.AS: $1,563.80 ▲ 3.00 (0.19%)ENR.DE: $160.06 ▼ -2.44 (-1.50%)GLEN.L: $535.10 ▼ -0.20 (-0.04%)IFX.DE: $81.12 ▲ 0.56 (0.70%)NOKIA.HE: $12.20 ▲ 0.20 (1.67%)RIO.L: $7,279.00 ▲ 15.00 (0.21%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

Sema4 Holdings Corp.

SMFR - NASDAQ

Identifiants & Marche

Ticker SMFR
ISIN US81663L1017
CIK 0001818331
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.